We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Guru Sonpavde

Guru Sonpavde MD

Bladder Cancer Director, Dana-Farber Cancer Institute, Boston, Massachusetts

Dr. Guru Sonpavde, MD, is the Bladder Cancer Director at the Dana-Farber Cancer Institute and is on the faculty of Harvard Medical School. He completed his fellowship in medical oncology at Indiana University. At Dana-Farber, he leads multiple cutting-edge clinical trials studying novel immunotherapy and targeted drugs to treat urological cancers, particularly bladder cancer. He is the national or international principal investigator on multiple clinical trials for bladder cancer. He has also led translational projects and developed prognostic classifications and clinical endpoints focused on bladder cancer. He is a member of Southwest Oncology Group (SWOG) and the Bladder Cancer Task Force of the National Cancer Institute Genitourinary Cancers Steering Committee.  

Recent Contributions to PracticeUpdate:

  1. Clinical Insights From Outcomes in Patients With Upper vs Lower Urinary Tract Urothelial Carcinoma
  2. Enfortumab Vedotin vs Chemotherapy for Advanced Urothelial Carcinoma
  3. Durvalumab for Patients With Metastatic Urothelial Carcinoma and Prior Chemotherapy
  4. ASCO GU 2021: Recommendations From Dr. Guru Sonpavde
  5. Plasma ctDNA Is a Tumor Tissue Surrogate and Enables Clinical-Genomic Stratification of Metastatic Bladder Cancer
  6. 2020 Top Stories in Bladder Cancer: Switch-Maintenance Avelumab Following First-Line Platinum-Based Chemotherapy—A New Paradigm in Advanced Urothelial Carcinoma
  7. Neoadjuvant Gemcitabine–Cisplatin Plus Radical Cystectomy–Pelvic Lymph Node Dissection for Muscle-Invasive Bladder Cancer
  8. Pembrolizumab Plus Acalabrutinib for Platinum-Resistant Metastatic Urothelial Carcinoma
  9. Preoperative Ipilimumab Plus Nivolumab in Locoregionally Advanced Urothelial Cancer
  10. Dr. Guru Sonpavde on the Results of the EV-201 Trial in the Cisplatin-Ineligible Post–PD-1/PD-L1 Inhibitor Cohort

Most Read This Week

Recently Updated